不同诱导化疗疗效对非高发区局部晚期鼻咽癌调强放疗同期化疗预后影响

doi:10.3760/cma.j.cn113030-20201130-00580

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To evaluate effect of different induction chemotherapy on the clinical efficacy of concurrent intensity-modulated radiotherapy (IMRT) and chemotherapy and identify the prognostic factors in non-endemic locally-advanced nasopharyngeal carcinoma patients. Methods Clinical data of 210 patients with stage Ⅲ-ⅣB(excluding stage T3-4N0M0) nasopharyngeal carcinoma treated in our hospital from 2012 to 2017 were retrospectively analyzed. According to the efficacy of different induction chemotherapy, all patients were divided into the effective group (14 cases of complete remission and 165 cases of partial remission) and ineffective group (31 cases of stability and 0 case of progression). Survival analysis was performed by Kaplan-Meier method. Multivariate analysis was conducted by using Cox′s regression model. Results Compared with the ineffective group, the 3-year overall survival (OS)(89.2% vs. 74.2%, P=0.005), recurrence-free survival (RFS)(93.0% vs. 81.9%, P=0.010) and progression-free survival (PFS)(80.2% vs. 58.1%, P=0.005) were significantly higher in the effective group, whereas the distant metastasis-free survival did not significantly differ between two groups (84.1% vs.69.7%, P=0.070). Multivariate analysis showed that the tumor response to induction chemotherapy was an independent prognostic factor for OS, RFS and PFS. Conclusions Tumor response to induction chemotherapy might be a prognostic factor for non-endemic locally-advanced nasopharyngeal carcinoma patients. Clinical prognosis of patients with poor response to induction chemotherapy is even worse. More intensive treatment and closer follow-up may be needed for these patients.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Sun Xueming
	Lu Xiaoxu
	Huang Rong
	Wu Hui

Key words： Nasopharygeal neoplasm/induction chemotherapy Nasopharygeal neoplasm/concurrentradiochemotherapy Radiotherapy intensity-modulated Prognosis

Received: 30 November 2020

Fund:Medical Science and Technology Development Program of Henan Province (Joint construction)(LHGJ20190632)

Corresponding Authors: Wu Hui, Email:wuhui7008@126.com

Cite this article:

Sun Xueming,Lu Xiaoxu,Huang Rong et al. Effect of different induction chemotherapy on clinical prognosis of patients with non-endemic locally-advanced nasopharyngeal carcinoma after concurrent chemotherapy with IMRT[J]. Chinese Journal of Radiation Oncology, 2021, 30(5): 434-439.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20201130-00580 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2021/V30/I5/434

[1] Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China[J]. Chin J Cancer, 2011, 30(2):114-119. DOI:10.5732/cjc.010.10377.
[2] Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma:a meta-analysis of the published literature[J]. J Clin Oncol, 2004, 22(22):4604-4612. DOI:10.1200/JCO.2004.10.074.
[3] Kwong DL, Sham JS, Au GK, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma:a factorial study[J]. J Clin Oncol, 2004, 22(13):2643-2653. DOI:10.1200/JCO.2004.05.173.
[4] Pan JJ, Ng WT, Zong JF, et al. Proposal for the 8^th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy[J]. Cancer, 2016, 122(4):546-558. DOI:10.1002/cncr.29795.
[5] Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma:a phase 3, multicentre, randomised controlled trial[J]. Lancet Oncol, 2016, 17(11):1509-1520. DOI:10.1016/S1470-2045(16)30410-7.
[6] Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma[J]. N Engl J Med, 2019, 381(12):1124-1135. DOI:10.1056/NEJMoa1905287.
[7] Liu LT, Tang LQ, Chen QY, et al. The prognostic value of plasma Epstein-Barr Viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2015, 93(4):862-869. DOI:10.1016/j.ijrobp.2015.08.003.
[8] Peng H, Chen L, Li WF, et al. Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma:a secondary analysis of a randomized phase 3 clinical trial[J]. Cancer, 2017, 123(9):1643-1652. DOI:10.1002/cncr.30520.
[9] 中国鼻咽癌临床分期工作委员会. 2010鼻咽癌调强放疗靶区及剂量设计指引专家共识[J]. 中华放射肿瘤学杂志,2011, 20(4):267-269. DOI:10.3760/cma.j.issn.1004-4221.2011.04.001.
Clinical Staging Committee of Nasopharyngeal Carcinoma in China. 2010 expert consensus on target area and dose design guidelines for nasopharyngeal carcinoma based on IMRT[J]. Chin J Radiat Oncol, 2011, 20(4):267-269. DOI:10.3760/cma.j.issn.1004-4221.2011.04.001.
[10] Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy:15-year experience in 789 patients treated at a single institution[J]. Cancer, 2006, 106(5):1154-1161. DOI:10.1002/cncr.21724.
[11] Visser JH, Wessels G, Hesseling PB, et al. Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia[J]. Pediatr Hematol Oncol, 2001,18(3):187-191. DOI:10.1080/088800101511 14804.
[12] Peng H, Chen L, Zhang Y, et al. The tumour response to induction chemotherapy has prognostic value for long-term survival outcomes after intensity-modulated radiation therapy in nasopharyngeal carcinoma[J]. Sci Rep, 2016, 6:24835. DOI:10.1038/srep24835.
[13] Hui EP, Ma BB, Leung SF, et al. Randomized phase Ⅱ trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma[J]. J Clin Oncol, 2009, 27(2):242-249. DOI:10.1200/JCO.2008.18.1545.
[14] Cao SM, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma:a phase Ⅲ multicentre randomised controlled trial[J]. Eur J Cancer, 2017, 75(1):14-23. DOI:10.1016/j.ejca.2016.12.039.
[15] Jian Zang, Chen Li, Man Xu, et al. Induction chemotherapy followed by concurrent chemoradiotherapy is benefit for advanced stage nasopharyngeal carcinoma with different nonkeratinizing carcinoma subtypes[J]. Sci Rep, 2018, 8(1):13318. DOI:10.1038/s41598-018-31050-z.
[16] Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation[J]. J Natl Cancer Inst, 2009, 101(7):498-506. DOI:10.1093/jnci/djp007.
[17] Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer[J]. N Engl J Med, 2007, 357(17):1705-1715. DOI:10.1056/NEJMoa070956.
[18] Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer[J]. N Engl J Med, 2007, 357(17):1695-1704. DOI:10.1056/NEJMoa071028.
[19] Peng H, Tang LL, Chen BB, et al. Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal carcinoma:a big-data intelligence platform-based analysis[J]. Oral Oncol, 2018, 79(1):40-46. DOI:10.1016/j.oraloncology.2018.02.011.